CLYM Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

13.710

Open

13.360

VWAP

13.32

Vol

1.45M

Mkt Cap

768.47M

Low

12.840

Amount

19.36M

EV/EBITDA(TTM)

Total Shares

57.26M

650.32M

EV/OCF(TTM)

P/S(TTM)

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.

Events Timeline

(ET)

2026-06-11

08:31:00

Climb Bio Announces Initial Data on Budoprutug

2026-05-29 (ET)

2026-05-29

16:20:00

Selling Stockholder Plans to Sell Up to 11.59M Shares

2026-05-07 (ET)

2026-05-07

07:20:00

Climb Bio CEO Discusses Clinical Progress of Budoprutug

News

7.5

07-06NASDAQ.COM

Analysis of Biotech Companies' Stock Performance

9.0

06-05Newsfilter

Climb Bio Shares CLYM116 Clinical Data and Future Plans

8.5

04-28seekingalpha

Climb Bio Secures $110M in Private Placement

8.5

04-28seekingalpha

Climb Bio Secures $110M in Private Placement

8.5

04-28seekingalpha

Climb Bio Secures $110M in Private Placement

8.5

04-28seekingalpha

Climb Bio Secures $110M in Private Placement

3 Analyst Rating

Wall Street analysts forecast CLYM stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

10.00

Averages

10.50

High

11.00

Current: 0.000

Low

10.00

Averages

10.50

High

11.00

BTIG

Julian Harrison

Buy

maintain

$19 -> $20

AI Analysis

2026-06-11

Reason

BTIG

Julian Harrison

Price Target

$19 -> $20

AI Analysis

2026-06-11

maintain

Buy

Reason

BTIG analyst Julian Harrison raised the firm's price target on Climb Bio to $20 from $19 and keeps a Buy rating on the shares. Budoprutug, an anti-CD19 monoclonal antibody, showed meaningful platelet responses in heavily pretreated adult immune thrombocytopenia patients in Phase 1b data, with strong B-cell depletion, durable platelet improvements in most patients, and a clean safety profile across dose cohorts, while additional data across higher doses and other indications are expected through 2026, the analyst tells investors in a research note.

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$15 -> $20

2026-05-12

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$15 -> $20

2026-05-12

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Climb Bio to $20 from $15 and keeps a Buy rating on the shares post the Q1 report. The firm says budoprutug clinical data catalysts are "fast approaching."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLYM

Unlock Now

Valuation Metrics

The current forward P/E ratio for Climb Bio Inc (CLYM.O) is 0.00, compared to its 5-year average forward P/E of -3.40. For a more detailed relative valuation and DCF analysis to assess Climb Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.40

Current PE

0.00

Overvalued PE

-1.58

Undervalued PE

-5.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-0.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

surging stocks between 10 to $20

Intellectia · 547 candidates

Price: $10.00 - $20.00Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

FSEA

First Seacoast Bancorp Inc

78.21M

VRDN

Viridian Therapeutics Inc

1.93B

BDSX

Biodesix Inc

151.02M

AIOS

AIOS Tech Inc

63.69M

ONEG

OneConstruction Group Ltd

175.36M

IART

Integra Lifesciences Holdings Corp

1.03B

list top 50 performing small caps

Intellectia · 84 candidates

Market Cap: 300.00M - 1.50BPrice: >= $5.00Moving Average Relationship: PriceAboveMA200Year Price Change Pct: >= $150.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

MGRT

Mega Fortune Co Ltd

1.45B

RLMD

Relmada Therapeutics Inc

734.22M

ANRO

Alto Neuroscience Inc

832.50M

BNAI

Brand Engagement Network Inc

331.86M

NINE

Nine Energy Service Inc

386.47M

STTK

Shattuck Labs Inc

555.53M

of all the listed stocks pick one please

Intellectia · 111 candidates

Price: $5.00 - $75.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEWeek Price Change Pct: >= $5.00One Day Rise Prob: >= 65Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

RYAM

Rayonier Advanced Materials Inc

685.47M

ADEA

Adeia Inc

2.26B

IMAX

Imax Corp

1.96B

IRON

Disc Medicine Inc

2.53B

FPI

Farmland Partners Inc

564.25M

SKT

Tanger Inc

4.31B

pennys stocks with high return

Intellectia · 265 candidates

Price: $1.00 - $15.00List Exchange: XNYS, XNAS, XASEQuarter Price Change Pct: >= $25.00Monthly Average Dollar Volume: >= 200,000

Ticker

Name

Market Cap$

CGTL

Creative Global Technology Holdings Ltd

70.49M

ERAS

Erasca Inc

3.05B

LPCN

Lipocine Inc

60.57M

IPSC

Century Therapeutics Inc

434.23M

NBY

NovaBay Pharmaceuticals Inc

594.28M

SIDU

Sidus Space Inc

234.80M

Whales Holding CLYM

Affinity Asset Advisors, LLC

RA Capital Management, L.P.

Kynam Capital Management, LP

ADAR1 Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Climb Bio Inc (CLYM) stock price today?

The current price of CLYM is 13.42 USD — it has increased 1.13

What is Climb Bio Inc (CLYM)'s business?

What is the price predicton of CLYM Stock?

Wall Street analysts forecast CLYM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLYM is10.50 USD with a low forecast of 10.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.